MED31

Across TCGA pan-cancer cohorts, MED31 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED31 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MED31 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED31 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where MED31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.874	0.216	<.001	54	view →
PDAC	DFS	Tertile	All	0.309	0.602	.002	24	view →
LSCC	OS	Tertile	II,III,IV	0.945	0.534	.003	19	view →
CCRCC	OS	Median	All	0.598	1.000	.002	16	view →
HNSC	DFS	Median	III,IV	0.653	0.897	.003	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED31–LUAD (DFS)

Open the LUAD breakdown →